secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001714899-23-000145
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali reports Q3 net loss $99.4M; cuts 2023 expense growth outlook to 15-20%
-----------------------------------------------------------------------------

- Net loss $99.4M (vs $103.3M); revenue $1.3M (vs $3.6M). Cash $1.12B.
- FY2023 cash op expense growth guidance reduced to 15-20% from prior 25-30%.
- Sanofi's eclitasertib failed CLE Phase 2; UC study continues. Biogen amended LRRK2 deal.
- Pipeline: DNL310 Phase 2/3 enrolling; DNL126 Phase 1/2 starting; OTV advancing 2 candidates to clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/0001714899-23-000145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000145/dnli-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001714899-23-000145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer